Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 5;33:110–126. doi: 10.1016/j.omtn.2023.06.001

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Molecular landscape and validation of MUC CSs

(A) The enrichment of three subtypes for different treatment-related signatures and bladder cancer-related signatures. (B) Regulon activity profiles for 23 TFs (top) and potential regulators associated with chromatin remodeling (bottom) of three subtypes. (C) Immune profiles in the TCGA-MUC cohort. The top annotation of the heatmap shows the immune enrichment score, stromal enrichment score, and DNA methylation of tumor-infiltrating lymphocytes. The top panel shows the expression of canonical immune checkpoint genes, and the bottom panel shows the enrichment levels of 24 TME-related immune cells. (D) Validation of MUC CSs in the nearest template of the META-MUC cohort. (E) Survival analysis of MUC CSs in the META-MUC cohort. (F) The consistency of CSs with NTP in the TCGA-MUC cohort. (G) The consistency of CSs with PAM in the TCGA-MUC cohort. (H) The consistency of NTP with PAM in the META-MUC cohort. (I) The consistency of NTP with PAM in the IMvigor-MUC cohort.